NCT04509414View on ClinicalTrials.gov

Intranasal Dexmedetomidine for Deep-sedated Pediatric Dental Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 10, 2020

Primary Completion Date

May 1, 2022

Study Completion Date

May 31, 2022

Conditions
Deep SedationDexmedetomidine
Interventions
DRUG

Dexmedetomidine

For dexmedetomidine group after ramdomization, an intranasal dose of 2ug/kg dexmedetomidine will be administrated.

DRUG

Midazolam

For midazolam group after ramdomization, an intranasal dose of 0.2mg/kg midazolam will be administrated.

Trial Locations (1)

100081

Peking University Hospital of Stomatology, Beijing

All Listed Sponsors
lead

Peking University

OTHER

NCT04509414 - Intranasal Dexmedetomidine for Deep-sedated Pediatric Dental Patients | Biotech Hunter | Biotech Hunter